Gilead's remdesivir meets main goal of trial in COVID-19 patients [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
Gilead's remdesivir meets main goal of trial in COVID-19 patients (Reuters) - Gilead Sciences Inc said on Wednesday its experimental antiviral drug, remdesivir, had met the main goal of a trial testing it in COVID-19 patients. The trial was being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), and more details on the data would be provided at an upcoming briefing by the NIAID, Gilead said.
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $125.00 price target on the stock.MarketBeat
- Gilead Prices $3.5 Billion of Senior Unsecured NotesBusiness Wire
- Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear [Yahoo! Finance]Yahoo! Finance
- Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV GlasgowBusiness Wire
GILD
Earnings
- 11/6/24 - Beat
GILD
Sec Filings
- 11/13/24 - Form FWP
- 11/13/24 - Form 424B5
- 11/12/24 - Form 10-Q
- GILD's page on the SEC website